Cabozantinib in Men With Castration-Resistant Prostate Cancer
Status:
Terminated
Trial end date:
2015-09-18
Target enrollment:
Participant gender:
Summary
This pilot clinical trial studies cabozantinib in treating men with castration-resistant
prostate cancer. Cabozantinib may stop the growth of tumor cells by blocking some of the
enzymes needed for cell growth.
Phase:
Phase 2
Details
Lead Sponsor:
University of Washington
Collaborators:
National Cancer Institute (NCI) Prostate Cancer Foundation